VEGFA and neoplasm: Intriguingly, the development of tumor‐specific targeting molecular probes has accelerated optical molecular imaging for the accurate determination of surgical margins in BCS.[19] For example, monoclonal antibodies, such as Bev and cetuximab have been developed to target VEGF‐A and epidermal growth factor receptor, which are characteristic tumor cell surface markers.